Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

The conversation discusses skepticism about the effectiveness of scalp tension theory and scalp massagers for hair regrowth, contrasting it with treatments like finasteride and minoxidil, which have more user-reported results. Participants question the belief in scalp tension theory, suggesting it may be a marketing tactic, while others argue for a multifactorial approach to hair loss.

The conversation discusses the molecular structures of compounds that reduce DHT levels, including finasteride and Ashwagandha. It explores the potential of using Ashwagandha topically as a 5a reductase inhibitor.

AH-001 is a new topical treatment designed to degrade androgen receptors, targeting the root cause of androgenetic alopecia without the side effects of oral treatments like finasteride. It has shown a strong safety profile and good local tolerability in early trials.

A user tried the Rapid Minoxidil Response Test (TrichoGene) and found they don't respond to topical Minoxidil, so they added tretinoin. The test is available internationally, and another user is considering ordering it.

The user has tried various hair loss treatments including topical minoxidil, oral finasteride, oral dutasteride, oral minoxidil, and exosome therapy, but none have been effective. They suspect trichodynia might be preventing these treatments from working.

A 26-year-old male considering a hair transplant is using topical finasteride and minoxidil, planning to start feminizing hormone replacement therapy (HRT) with estrogen and spironolactone. Many suggest waiting to see the effects of HRT, which may significantly regrow hair, before deciding on a transplant, and recommend adding microneedling and possibly switching to oral treatments for better results.

A user is seeking non-transplant hair treatments in Seoul, such as scalp detox, PRP, and exosomes, before considering a future transplant with Dr. Zarev. They want to explore options that improve hair health without undergoing a transplant immediately.

The conversation discusses the complexity of reversing hair loss and the need for a treatment that specifically targets DHT levels without affecting other bodily functions. It mentions finasteride as a current treatment but highlights the desire for a solution that works solely on the scalp.

PP405 trials have completed phase 2a, showing promising results with a 31% stat for hair density increase, and are moving directly to phase 3. Detailed results will be presented at a medical conference in 2026.

The user is considering a crown transplant but is advised to try topical finasteride or dutasteride alongside minoxidil first, as transplants without these treatments may not be effective. They experienced lower libido with oral finasteride and are exploring other options like topical treatments and red light therapy.

PP405 is a new hair loss treatment in phase 2 trials that may promote hair growth by increasing lactate production and activating hair follicle stem cells. It could potentially replace hormone-disrupting treatments like Minoxidil and finasteride.

SCUBE3 and Amplifica's progress in hair loss treatment is being discussed, with inquiries about their current status and clinical trials. No specific updates or new information are provided in the conversation.

Blocking DHT is not a complete solution for hair loss; instead, altering the scalp's response to DHT may be more effective. Topical finasteride and minoxidil are current treatments, but future approaches may involve bioengineering, gene therapy, and inflammation control.

The GT20029 tincture, a topical androgen receptor degrader, showed significant hair growth and good safety in a China Phase II trial for male androgenetic alopecia (AGA), with the 1% dose twice weekly identified as optimal. The company plans to initiate Phase III trials in China and Phase II in the U.S., and the treatment also shows promise for acne.

Rapamycin, finasteride, and minoxidil are discussed as a strategy for hair loss prevention and reversal. Pulsed dosing of rapamycin is suggested to avoid conflicting effects with minoxidil.

Topical finasteride results in plasma levels 100 times lower than oral finasteride, potentially reducing systemic side effects. Users report similar efficacy with fewer side effects, suggesting a preference for topical application.

The trial for TDM-105795 has been completed, and it was in phase 2A. The discussion seeks input on the next phases, 2B or 3, based on safety and efficacy.

Scientists found hidden stem cells that might reactivate hair growth. The discussion includes treatments like Minoxidil, finasteride, and RU58841.

Rejuv-3X, a topical blend with GHK-Cu, AHK-Cu, and JXL-089, is used for hair loss, offering a targeted option without finasteride's side effects. The user plans to combine it with microneedling for enhanced results.

The conversation discusses using NAC and quercetin as supplements for hair loss, with some users also mentioning finasteride. NAC is highlighted for its potential benefits, but concerns about its safety and absorption are also raised.

Verteporfin may improve hair transplant outcomes and reduce scarring, potentially allowing patients to avoid finasteride. Dr. Barghouthi seeks collaborations, volunteers, and financial support for research on verteporfin.org.

Stemson's presentation discussed using induced pluripotent stem cell technology to create new hair follicles for treating hair loss. The conversation also mentions treatments like Minoxidil, finasteride, and RU58841.

The clinic diagnosed the user with NW3 and AGA, noting thinning hair despite using finasteride for 3 years, and suggested PRP and Mesotherapy before considering a transplant. The user questions the necessity of these treatments without confirming retrograde alopecia and its treatability.

PP405 shows promise in hair loss treatment, but stem cell therapy using adipose-derived stem cells and ATP also successfully reversed androgenetic alopecia in mice. Stem cell therapy is costly, and some doubt the effectiveness of PP405 based on press releases.

Longitudinal partial follicular unit transplantation involves extracting part of the donor follicular unit, allowing the donor area to maintain hair production and potentially increasing transplant yield. The conversation questions if this method is practiced in clinics or remains theoretical, and whether it relates to hair cloning or multiplication.

The conversation discusses doubts about the effectiveness of topical finasteride for hair loss, suggesting that DHT could be produced elsewhere in the body and affect the scalp. It proposes that androgen receptor antagonists like spironolactone and clascoterone might be more effective as they could prevent this potential bypass mechanism.

Hair transplants are not always a long-term solution for young people with significant hair loss, as they can lead to scarring and require ongoing maintenance. Medications like finasteride and dutasteride are effective for many, but not all, and should be considered before opting for a transplant.

Calecim (PTT-6) Advanced Hair System is a 6-week hair restoration product using stem cell-derived ingredients to stimulate hair growth. Users are skeptical, calling it overpriced and ineffective, suggesting alternatives like LLLT devices or PRP treatments.

HairStemCell Transplant claims to reuse the donor area without removing the entire hair cell, but results in finer hair that may not regrow after cycles. The technique is costly and less effective than traditional transplants for full coverage.

Effective hair growth treatments include finasteride, minoxidil, dutasteride, and hair transplants, with additional options like microneedling, low-level laser therapy, and PRP showing some benefits. Newer treatments such as GHK-Cu peptides and ketoconazole shampoo are promising, while others like saw palmetto and biotin are less effective unless deficiencies exist.